Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Caryn E GoodUniversity Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Ayman M AbdelhamedUniversity Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
Andrew R MackDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-0131-7996
Christopher R BethelResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Steven H MarshallResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Andrea M HujerResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Kristine M HujerResearch Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Robin PatelDivision of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6344-4141
David van DuinDivision of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0003-4784-3227
Vance G FowlerDuke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA.
Krisztina M Papp-WallaceCase Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-9976-7898
Robert A BonomoDepartment of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.ORCID 0000-0002-3299-894X
Funding
Antibacterial Resistance Leadership Group (ARLG)UM1AI104681 · NIAID · DUKE UNIVERSITY · PI Vance G. Fowler, Henry F HENRY CHAMBERS · 2013 to 2026
$180.8M
Broad-spectrum, Orally Bioavailable Beta-lactamase Inhibitors for BiodefenseR01AI111539 · NIAID · VENATORX PHARMACEUTICALS, INC. · PI BURNS, CHRISTOPHER JOHN, XERRI, LUIGI · 2014 to 2017
$6.1M
Development of New Beta-Lactamase Inhibitors for Resistant Category B Food/Water-R01AI089512 · NIAID · VENATORX PHARMACEUTICALS, INC. · PI BURNS, CHRISTOPHER JOHN · 2010 to 2012
$4.1M
Advancement to IND of novel BLI for pairing with cefiximeR44AI109879 · NIAID · VENATORX PHARMACEUTICALS, INC. · PI XERRI, LUIGI · 2017 to 2019
$3.0M
Broad-spectrum, orally-bioavailable beta-lactamase inhibitorsR43AI109879 · NIAID · VENATORX PHARMACEUTICALS, INC. · PI CHU, GUO-HUA · 2014 to 2015
$599k
Molecular Epidemiology of Carbapenem-Resistant Klebsiella pneumoniaeR21AI114508 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., VAN DUIN, DAVID · 2015 to 2016
$445k
The Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–
Targeting Burkholderial β-lactamases: Structure, function, and regulationI01BX002872 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI DONSKEY, CURTIS, PAPP-WALLACE, KRISZTINA MARGARET · 2016 to 2023
–
BLRD VA I01 BX001974BLRD VA I01 BX002872HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) HHSN272201600029C,R44AI109879,R01AI089512,R01AI111539,R43AI109879HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R21AI114508NIAID NIH HHS HHSN272201600029CNIAID NIH HHS R01 AI089512NIAID NIH HHS R01 AI111539NIAID NIH HHS R21 AI114508NIAID NIH HHS R43 AI109879NIAID NIH HHS R44 AI109879NIAID NIH HHS UM1 AI104681U.S. Department of Health and Human Services (HHS) 75A50123C00050U.S. Department of Veterans Affairs (VA) 1I01BX001974U.S. Department of Veterans Affairs (VA) 1I01BX002872
6 · The paper itself
Abstract
Ledaborbactam (formerly VNRX-5236), a bicyclic boronate β-lactamase inhibitor with activity against class A, C, and D β-lactamases, is under development as an orally bioavailable etzadroxil prodrug (VNRX-7145) in combination with ceftibuten for the treatment of urinary tract infections. At ceftibuten breakpoints of ≤1 mg/L (EUCAST) and ≤8 mg/L (CLSI), 92.5% and 99.0%, respectively, of 200 carbapenem-resistant
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
ARGONAUT-IV: susceptibility of carbapenemase-producing · full record | OpenQuestion